Read Occupational Therapist Samar Muslemani’s Early Career Blog
Read the latest early career blog post, from NMD4C member Samar Muslemani, OT, M.Sc.
Excerpt:
“Occupational therapy is where science, creativity, and compassion collide”
This is a quote from Jessica Kensky, a survivor of the 2013 Boston Marathon bombing and keynote speaker at the 2016 American Occupational Therapy Association welcome ceremony. To me, this quote represents exactly what I love about my profession. Pursuing a PhD allows me to develop these three elements even further.
Samar Muslemani holds a Master’s Degree in Occupational Therapy and has been practicing in Saguenay, Québec since 2018. She is a doctoral student with the University of Sherbrooke. She aims to better understand the functional impacts of cognitive impairments in people living with myotonic dystrophy type 1. She completed a research Master’s Degree in Health Sciences in August 2021. Her project aimed to document independence and social participation of adults living with childhood phenotype of DM1. She received a bursary of the Fonds de recherche du Québec – Santé (FRQS), and has assessed patients both in Canada and France as part of her research project. Native from Saguenay-Lac-Saint-Jean region, she is interested in offering more support to patients and families with neuromuscular diseases (NMD) in her native region and internationally. Both in her research and clinical practice, she has worked with various NMDs, such as recessive spastic ataxia of Charlevoix-Saguenay, oculopharyngeal muscular dystrophy and Charcot-Marie-Tooth diseases. She is the first author of a practical guideline to support occupational therapists in addressing sexuality with their NMD patients.
Within the NMD4C, Samar supports the Knowledge Translation team through developing knowledge and skills, defining barriers, and reducing the knowledge-to-action gap by developing various tools including clinical practice guidelines in the NMD field.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.